AP2815A - Compositions comprising nebivolol - Google Patents

Compositions comprising nebivolol

Info

Publication number
AP2815A
AP2815A AP2007003870A AP2007003870A AP2815A AP 2815 A AP2815 A AP 2815A AP 2007003870 A AP2007003870 A AP 2007003870A AP 2007003870 A AP2007003870 A AP 2007003870A AP 2815 A AP2815 A AP 2815A
Authority
AP
ARIPO
Prior art keywords
nebivolol
compositions
Prior art date
Application number
AP2007003870A
Other languages
English (en)
Other versions
AP2007003870A0 (en
Inventor
Peter Bruce Bottini
Eric Davis
John O'donnell
Original Assignee
Mylan Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35449867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2815(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mylan Lab Inc filed Critical Mylan Lab Inc
Publication of AP2007003870A0 publication Critical patent/AP2007003870A0/xx
Application granted granted Critical
Publication of AP2815A publication Critical patent/AP2815A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2007003870A 2004-06-04 2005-06-01 Compositions comprising nebivolol AP2815A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57742304P 2004-06-04 2004-06-04
US11/141,235 US7803838B2 (en) 2004-06-04 2005-05-31 Compositions comprising nebivolol
PCT/US2005/019111 WO2005117858A2 (en) 2004-06-04 2005-06-01 Compositions comprising nebivolol

Publications (2)

Publication Number Publication Date
AP2007003870A0 AP2007003870A0 (en) 2007-02-28
AP2815A true AP2815A (en) 2013-12-31

Family

ID=35449867

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007003870A AP2815A (en) 2004-06-04 2005-06-01 Compositions comprising nebivolol

Country Status (13)

Country Link
US (3) US7803838B2 (de)
EP (1) EP1753418B1 (de)
KR (1) KR101236166B1 (de)
CN (1) CN102188708A (de)
AP (1) AP2815A (de)
AT (1) ATE509627T1 (de)
AU (1) AU2005249514B2 (de)
CA (1) CA2569881A1 (de)
IL (1) IL179999A (de)
NZ (1) NZ551910A (de)
RU (1) RU2403037C2 (de)
SG (1) SG152255A1 (de)
WO (1) WO2005117858A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
EP1839658A1 (de) * 2006-03-30 2007-10-03 Hexal A/S Pharmazeutische Zusammensetzungen enthaltend mikronisiertes Nebivolol
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EA200900815A1 (ru) * 2006-12-18 2009-12-30 Кардос Аб Новая комбинация, предназначенная для лечения воспалительных нарушений
US20100168137A1 (en) * 2006-12-20 2010-07-01 Johan Raud Combination for use in the treatment of inflammatory disorders
US20100056552A1 (en) * 2007-03-30 2010-03-04 Johan Raud Combination for use in the treatment of inflammatory disorders
ITMI20070890A1 (it) * 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
US20080305186A1 (en) * 2007-06-11 2008-12-11 Board Of Regents, The University Of Texas System Method and Composition for the Treatment of Cardiac Hypertrophy
CA2637979A1 (en) * 2007-07-26 2009-01-26 Mylan Laboratories, Inc. Treatment of cardiovascular disease in mexican americans using nebivolol
US20110015261A1 (en) * 2007-08-03 2011-01-20 Zleepax Europe ApS Use of a composition comprising at least one beta-blocker for the treatment of sleep disorders
EP2240022B1 (de) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Oxycodone und Promethazine enthaltende zweischichtige Tabletten
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
WO2009125168A1 (en) * 2008-04-07 2009-10-15 Cardoz Ab New combination for use in the treatment of inflammatory disorders
US20110028510A1 (en) * 2009-02-18 2011-02-03 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections
GB2471303A (en) 2009-06-24 2010-12-29 Bell Flavors & Fragrances Duft Und Aroma Gmbh Microparticles and method of making microparticles
US20110263668A1 (en) * 2009-07-01 2011-10-27 The Johns Hopkins University Beta 3-Adrenoreceptor Agonists for the Treatment of Cardiac Hypertrophy and Heart Failure
EP2451274B1 (de) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
USD661900S1 (en) 2010-02-22 2012-06-19 Bajer Design & Marketing, Inc. Collapsible structure
KR20110130872A (ko) * 2010-05-28 2011-12-06 현대약품 주식회사 결정형 염산 네비볼롤을 포함하는 약학 조성물 및 제조방법
WO2012027557A1 (en) * 2010-08-26 2012-03-01 The Regents Of The University Of Colorado, A Body Corporate SELECTIVE INHIBITION OF β 1- ADRENERGIC RECEPTORS FOR THE TREATMENT OF PEDIATRIC HEART FAILURE
CN104619345A (zh) * 2012-05-18 2015-05-13 罗达制药有限公司 液体制剂
WO2014031161A1 (en) * 2012-08-22 2014-02-27 Forest Laboratories Holdings Limited Chemical compositions
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
PE20160520A1 (es) * 2013-07-26 2016-05-31 Sanofi Sa Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
WO2016069717A1 (en) * 2014-10-28 2016-05-06 MiRagen Therapeutics, Inc. Inhibitors of mirnas in regulation of arterial stiffness and uses thereof
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
WO2020236631A1 (en) * 2019-05-17 2020-11-26 Alsar Ltd Partnership Flecainide combination and controlled-release formulations for treating heart diseases
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
KR20250171439A (ko) 2019-08-01 2025-12-08 인카다 테라퓨틱스, 인크. 항부정맥 제제
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
US12576026B2 (en) * 2020-07-08 2026-03-17 Extrovis Ag Formulations of nebivolol
CN117398415B (zh) * 2022-07-08 2026-08-11 深圳市人民医院 嗜黏蛋白阿克曼菌以及相关组合物在制备血管钙化抑制剂中的应用
IT202400011176A1 (it) * 2024-05-16 2025-11-16 Alba Res S R L Composizioni per il trattamento dell'ipertensione arteriosa

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4780401A (en) * 1984-04-09 1988-10-25 Ciba-Geigy Corporation Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) * 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US5387413A (en) * 1985-06-14 1995-02-07 The Research Foundation Of State University Of New York Method of inhibiting thrombus formation by the 7E3 monoclonal antibody
US4894437A (en) * 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) * 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4772684A (en) * 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US4904646A (en) * 1987-05-22 1990-02-27 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US5017716A (en) * 1987-05-22 1991-05-21 E.R. Squibb & Sons, Inc. Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4997837A (en) * 1987-09-08 1991-03-05 Warner-Lambert Company 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5089471A (en) * 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US4980283A (en) * 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5034512A (en) * 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) * 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) * 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US5001144A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4994494A (en) * 1987-12-21 1991-02-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4939143A (en) * 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5001128A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US5081127A (en) * 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US4946864A (en) * 1988-02-01 1990-08-07 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5036054A (en) * 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5021453A (en) * 1988-03-02 1991-06-04 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
EP0331250B1 (de) * 1988-03-02 1994-04-13 Merck & Co. Inc. Antihypercholesterolemisches Mittel
US6545040B1 (en) 1988-03-23 2003-04-08 Janssen Pharmaceutica N.V. Method of lowering the blood pressure
US4920109A (en) * 1988-04-18 1990-04-24 Merck & Co., Inc. Antifungal compositions and method of controlling mycotic infections
US5166171A (en) * 1988-05-13 1992-11-24 Hoechst Aktiengesellschaft 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiphenoxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, and in treating hypercholesterolemia
US5036053A (en) * 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
US4897402A (en) * 1988-06-29 1990-01-30 Merck & Co., Inc. 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors
US4963538A (en) * 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
IT1226726B (it) * 1988-07-29 1991-02-05 Zambon Spa Composti attivi come inibitori della biosintesi del colesterolo.
US5196440A (en) * 1988-07-29 1993-03-23 Zambon Group S.P.A. Compounds active as inhibitors of the cholesterol biosynthesis
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
DE3841520A1 (de) * 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US4906657A (en) * 1988-12-21 1990-03-06 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US4957940A (en) * 1988-12-21 1990-09-18 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US4950675A (en) * 1988-12-21 1990-08-21 Warner-Lambert Company Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis
US5106835A (en) * 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US4923861A (en) * 1989-02-07 1990-05-08 Warner-Lambert Company 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5130306A (en) * 1989-03-13 1992-07-14 Merck & Co., Inc. 5-Oxygenated HMG-COA reductase inhibitors
US5132312A (en) * 1989-03-27 1992-07-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
DE4004820A1 (de) * 1989-08-05 1991-04-25 Bayer Ag Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5102911A (en) * 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
US4970231A (en) * 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US4992429A (en) * 1989-08-24 1991-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel HMG-COA reductase inhibitors
US5098931A (en) * 1989-08-31 1992-03-24 Merck & Co., Inc. 7-substituted HMG-CoA reductase inhibitors
US5098924A (en) * 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) * 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US4946860A (en) * 1989-11-03 1990-08-07 Rorer Pharmaceutical Corporation Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5025000A (en) * 1990-03-02 1991-06-18 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitor compounds
US5064965A (en) * 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) * 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5085992A (en) * 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
US5112857A (en) * 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5071837A (en) * 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5182298A (en) * 1991-03-18 1993-01-26 Merck & Co., Inc. Cholesterol lowering agents
US5256689A (en) * 1991-05-10 1993-10-26 Merck & Co., Inc. Cholesterol lowering compounds
US5135935A (en) * 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
US5250435A (en) * 1991-06-04 1993-10-05 Merck & Co., Inc. Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
US5202327A (en) * 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5260332A (en) * 1992-02-07 1993-11-09 Merci & Co., Inc. Cholesterol lowering compounds
US5262435A (en) * 1992-02-10 1993-11-16 Merck & Co., Inc. Cholesterol lowering compounds
US5286895A (en) * 1992-02-19 1994-02-15 Merck & Co., Inc. Cholesterol lowering compounds
US5302604A (en) * 1992-03-09 1994-04-12 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
US5369125A (en) * 1992-07-17 1994-11-29 Merck & Co., Inc. Cholesterol-lowering agents
US5283256A (en) * 1992-07-22 1994-02-01 Merck & Co., Inc. Cholesterol-lowering agents
US5317031A (en) * 1992-10-19 1994-05-31 Merck & Co., Inc. Cholesterol lowering compounds
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
HU226208B1 (en) 1994-12-28 2008-06-30 Janssen Pharmaceutica Nv Use of nebivolol for producing anti-atherogenic pharmaceuticals
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6541479B1 (en) 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
AU7365900A (en) 1999-09-08 2001-04-10 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US6635273B1 (en) 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20050074487A1 (en) 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
GB9930688D0 (en) 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
EP1257272A4 (de) * 2000-02-23 2004-12-15 Alteon Inc Thiazoliumverbindungen und behandlungen von erkrankungen im zusammenhang mit derproteinalterung
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
US20030176426A1 (en) 2000-07-13 2003-09-18 Alteon, Inc. Method for treating fibrotic diseases or other indications with imidazolium agents
EP2085086A3 (de) 2000-07-13 2009-11-25 Synvista Therapeutics, Inc. Methode zur Behandlung von kongestiver Herzinsuffizienz oder diabetischer Nephropathy
US20040235809A1 (en) 2000-07-27 2004-11-25 Alexander John C Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
US6595926B1 (en) 2000-09-07 2003-07-22 John H. Laragh Method for evaluating and treating hypertension
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
WO2002067851A2 (en) 2000-12-29 2002-09-06 Alteon, Inc. Method for treating fibrotic diseases or other indications iiic
WO2002053101A2 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
NZ542090A (en) 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
PT1363668E (pt) 2001-01-26 2007-11-07 Schering Corp Combinaçoes de sequestrante(s) de ácidos biliares e inibidor(es) de absorção de esterol e tratamento de indicações vasculares
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1385548B1 (de) 2001-01-26 2007-05-23 Schering Corporation Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
TW200840563A (en) 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
EP1364957B1 (de) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE437637T1 (de) 2001-05-02 2009-08-15 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
WO2002096415A2 (en) 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
CA2448294A1 (en) 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications vi
WO2002096363A2 (en) 2001-05-30 2002-12-05 Alteon, Inc. Method for treating fibrotic diseases or other indications
US7271153B2 (en) 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE60229406D1 (de) 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US20030119808A1 (en) 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
FR2830856B1 (fr) 2001-10-15 2004-07-30 Pechiney Aluminium Precurseur de revetement et procede pour revetir un substrat d'une couche refractaire
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
WO2003097011A1 (en) 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
AU2003240670A1 (en) * 2002-05-17 2003-12-02 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
EP1553089B1 (de) 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
BRPI0313290B1 (pt) 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US6869966B2 (en) 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
AU2003272903A1 (en) 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
WO2004050652A1 (ja) 2002-11-29 2004-06-17 Banyu Pharmaceutical Co., Ltd. 新規アゾール誘導体
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2004209505B2 (en) 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP4408197B2 (ja) * 2003-04-07 2010-02-03 パイオニア株式会社 表示画面の焼付防止装置及び焼付防止方法
HK1078086A1 (en) 2003-04-09 2006-03-03 日本烟草产业株式会社 Heteroaromatic pentacyclic compound and medicinal use thereof
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
ATE455547T1 (de) 2003-04-11 2010-02-15 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
US20060100235A1 (en) 2003-04-11 2006-05-11 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
US20050014747A1 (en) 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
US20060148721A1 (en) 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
WO2004113359A1 (ja) 2003-06-20 2004-12-29 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
US20050032879A1 (en) 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
KR20060085686A (ko) 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
WO2005046797A2 (en) 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
WO2005099699A1 (en) 2004-04-07 2005-10-27 Sepracor Inc. Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US20060014828A1 (en) 2004-07-16 2006-01-19 Nitromed, Inc. Compositions and methods related to heart failure
EP1807070A1 (de) 2004-09-29 2007-07-18 Schering Corporation Kombinationen aus substituierten azetidinonen und cb1-antagonisten
US20060142288A1 (en) 2004-12-07 2006-06-29 Stephen Peroutka Combinations and methods for headaches

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gremmler, B. et al, Experimental and Clinical Cardiology, 2003, 7(4):193-198 *
McNeely, W. et al, Drugs, 1999, 57(4):633-651 *
Teoh, Y.P. et al, British Journal of Diabetes and Vascular Disease, 2003, 3(4):300-301 *

Also Published As

Publication number Publication date
IL179999A (en) 2013-08-29
WO2005117858A2 (en) 2005-12-15
SG152255A1 (en) 2009-05-29
RU2006147220A (ru) 2008-07-20
KR20070044833A (ko) 2007-04-30
EP1753418A2 (de) 2007-02-21
US20050272810A1 (en) 2005-12-08
US7803838B2 (en) 2010-09-28
CA2569881A1 (en) 2005-12-15
AU2005249514A1 (en) 2005-12-15
RU2403037C2 (ru) 2010-11-10
US20090227646A1 (en) 2009-09-10
AP2007003870A0 (en) 2007-02-28
NZ551910A (en) 2010-05-28
WO2005117858A3 (en) 2006-03-02
ATE509627T1 (de) 2011-06-15
AU2005249514B2 (en) 2011-04-07
CN102188708A (zh) 2011-09-21
KR101236166B1 (ko) 2013-02-22
US20090215844A1 (en) 2009-08-27
EP1753418B1 (de) 2011-05-18

Similar Documents

Publication Publication Date Title
AP2007003870A0 (en) Compositions comprising nebivolol
ZA200904425B (en) Nemathical compositions
EP1718714A4 (de) Markierstoffhaltige zusammensetzungen
GB0409375D0 (en) Phytoactive composition
ZA200706287B (en) Glucoronidated Nebivolol
GB0405406D0 (en) Anti-vaginitis compositions
GB0416861D0 (en) Composition
GB0414803D0 (en) Composition
GB0410038D0 (en) Composition
EP1726304A4 (de) Solifenacin enthaltende zusammensetzung
AP2896A (en) Compositions comprising nebivolol
GB0417357D0 (en) Composition
GB0415981D0 (en) Composition
ZA200701197B (en) Compositions
GB0410140D0 (en) Compositions
ZA200710355B (en) Compositions comprising nebivolol
AU303643S (en) Table
ZA200610708B (en) Compositions comprising nebivolol
GB0420627D0 (en) Monoglyceride-containing compositions
GB0425445D0 (en) Novel compositions
GB0417388D0 (en) Composition
GB2418924B (en) Weathered-effect composition
HK1094774A (en) Compositions comprising nebivolol
GB0409598D0 (en) Composition
GB0412544D0 (en) Compositions